Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticaria

Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticaria Dear Editor,Chronic urticaria (CU) is a group of common and debilitating conditions containing both chronic spontaneous urticaria (CSU) and chronic inducible urticarias (CIndU) including cold urticaria (ColdU). While antihistamines and omalizumab are effective treatments for both CSU and ColdU, many patients show insufficient response to either or both of these treatments, and additional and better therapies are needed.Reslizumab is a humanized monoclonal anti‐interleukin 5 (IL‐5) antibody licensed for the treatment of severe eosinophilic asthma. IL‐5 is the major cytokine responsible for the recruitment, activation and survival of eosinophils, which play a crucial role in causing tissue and subsequent airway hyperresponsiveness in asthma. Previously, we demonstrated that eosinophil numbers are increased in the skin of CSU patients. Recently, we reported that treatment with mepolizumab, another monoclonal antibody against IL‐5, can result in the rapid remission of CSU.Here, we report the case of a 43‐year‐old woman with severe non‐allergic refractory eosinophilic asthma (non‐smoker, IgE 136 kU/L, skin prick test negative to pollen, mites and other common aeroallergens, eosinophils 540/μL, FEV1 75% predicted, asthma control test (ACT) 15 points, four asthma exacerbations in the last year, therapy including prednisolone 50–25 mg/day, LAMA and LABA) who was successfully treated for her asthma with http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of the European Academy of Dermatology & Venereology Wiley

Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticaria

Loading next page...
 
/lp/wiley/benefit-from-reslizumab-treatment-in-a-patient-with-chronic-VmYxa4zKmC
Publisher
Wiley
Copyright
Copyright © 2018 European Academy of Dermatology and Venereology
ISSN
0926-9959
eISSN
1468-3083
D.O.I.
10.1111/jdv.14594
Publisher site
See Article on Publisher Site

Abstract

Dear Editor,Chronic urticaria (CU) is a group of common and debilitating conditions containing both chronic spontaneous urticaria (CSU) and chronic inducible urticarias (CIndU) including cold urticaria (ColdU). While antihistamines and omalizumab are effective treatments for both CSU and ColdU, many patients show insufficient response to either or both of these treatments, and additional and better therapies are needed.Reslizumab is a humanized monoclonal anti‐interleukin 5 (IL‐5) antibody licensed for the treatment of severe eosinophilic asthma. IL‐5 is the major cytokine responsible for the recruitment, activation and survival of eosinophils, which play a crucial role in causing tissue and subsequent airway hyperresponsiveness in asthma. Previously, we demonstrated that eosinophil numbers are increased in the skin of CSU patients. Recently, we reported that treatment with mepolizumab, another monoclonal antibody against IL‐5, can result in the rapid remission of CSU.Here, we report the case of a 43‐year‐old woman with severe non‐allergic refractory eosinophilic asthma (non‐smoker, IgE 136 kU/L, skin prick test negative to pollen, mites and other common aeroallergens, eosinophils 540/μL, FEV1 75% predicted, asthma control test (ACT) 15 points, four asthma exacerbations in the last year, therapy including prednisolone 50–25 mg/day, LAMA and LABA) who was successfully treated for her asthma with

Journal

Journal of the European Academy of Dermatology & VenereologyWiley

Published: Jan 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off